This Texas company thinks canines deserve clean air, too. Courtesy photo

Leave it to an Austin company to give us what we really need during this pandemic: dog face masks. Unlike their human companions, however, these are not for use in the fight against COVID-19.

On August 27, locally owned The Good Air Team announced the release of its K9 Mask, an N95-caliber snout shield for dogs. Though they resemble muzzles, these specially designed masks filter smog, emissions, pollens, smoke from wildfires, dust, and even bacteria.

Basically, says the company, whenever a human is advised to wear a mask for environmental reasons, so should a canine. Exposure to toxic particles — particularly smoke — can cause pulmonary disease and vision problem in pups, among other issues.

Each mask is washable and outfitted with a removable four-layer air filter to help remove particles from the air as the dog breathes in. The air filter adheres to the Centers for Disease Control's requirements for an N95 mask, a hospital-grade face covering that filters 95 percent of the toxins in air.

Upon exhaling, the mask uses an "exhaust valve" to release air from the mask. The company claims the valve even releases heat to cool off a panting dog.

"Wildfires in places like California the last several years have unfortunately become the new normal. Finding solutions to the problems of air pollution, like wildfire smoke, is the number one goal of the Good Air Team," says CEO Kirby Holmes in a release.

Holmes and co-owner Evan Daugherty launched The Good Air Team in 2018. The K9 Mask project is the result of the company's successful March 2019 Kickstarter, where it surpassed its $10,000 goal to bring the line into production.

K9 Masks are available online for $59, come in small, medium, and large sizes, and are outfitted with adjustable neck and muzzle straps. Special five-packs of air filters can be purchased for an additional $24.88.

Adds Holmes: "We are empowering dog owners with new solutions to protect their pet's health."

------

This article originally ran on CultureMap.

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Houston-based veterinary biotech startup modernizes cancer treatments for dogs

Paw-dern medicine

More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies recently accomplished a significant milestone. In October, CAVU's specialized immunotherapy was administered to its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals."

At CAVU, O'Connor dedicates her time to modernizing cancer care for dogs by developing an Autologous Prescription Product, otherwise known as adoptive T-cell therapy for dogs. The T-cell therapy is currently offered as a companion treatment to other canine cancer treatments, such as chemotherapy, radiation or surgery, O'Connor said.

Historically, cancer research for animals has lagged behind that of humans, and cancer diagnoses have come late due to the language barrier, O'Connor said. Of the dogs who enter remission, a majority of them relapse within 10 months to one year, she said.

"A majority [of dogs] are diagnosed at stage four, and you have to become very aggressive," O'Connor said. "For B-cell lymphoma, with the current treatments right now and the current standard of [therapies], less than 20 percent make it to two years post-diagnosis."

Launching CAVU
O'Connor first began studying T-cell therapy for humans with cancer during her post-doctoral fellowship at M.D. Anderson Cancer Center. Her fellowship also partnered with Texas A&M University's Small Animal Hospital to develop a clinical trial studying the effects of adoptive T-cell therapies on dogs with B-cell lymphoma.

T-cell therapy is a cellular-based treatment in which a type of white blood cells — or the cells that fight off tumors and infections — are harvested from blood samples drawn from patients. The cells are then injected back into the patient through an IV to fight the cancerous cells, O'Connor said.

Unexpectedly, O'Connor's 19-year-old dog, Bubbles, was diagnosed with transitional cell carcinoma in 2008 and later dying from it in December 2009. Five years later, O'Connor's sister's 6-year-old dog, Daisy, also died from transitional cell carcinoma. O'Connor said she remembers feeling helpless as she watched the dogs succumb to the disease.

"I was giving them drugs and protocols that were from 1980 … and I was really upset that there wasn't much more we could do for our dogs — especially because I treat my dogs like family," O'Connor said.

That was when O'Connor realized she wanted to help prevent other people from feeling the pain of losing their furry family members. While T-cell therapy is not a new method of treating cancer in humans, O'Connor focused on modifying the serum to create a treatment plan appropriate for dogs.

However, launching a company focusing specifically on treating cancer in animals was not without its challenges; O'Connor said she had to learn how to start a business, make industry connections, and adopt an entrepreneurial mindset.

To help with this, CAVU also connected with various entrepreneurial accelerators, such as Houston Technology Center and Station Houston, which are associations that help place young businesses in front of investors.

CAVU later became a member of the Houston Angel Network — a group of private investors of high net worth individuals that as a group invest in startups. By presenting her business to HAN and its investors, CAVU was able to gain financial backing.

CAVU also recently joined the Capital Factory in early 2018, an Austin-based accelerator program for entrepreneurs in Texas. O'Connor said the program has helped her meet investors, mentors and other startups.

"The way I overcame a lot of this [the early challenges] is by education, listening and trying to navigate and talk with as many of the right people as I could that had experience," she said.

The future of CAVU
Since CAVU treated its first patient in October, CAVU's adoptive T-cell therapy treatment has been administered to six dogs, O'Connor said. CAVU's T-cell therapy is currently available at more than 12 veterinary clinics across the country, including clinics in Texas, Florida, Pennsylvania, New York, North Carolina, and Missouri.

Additionally, four Houston-area clinics currently offer the T-cell therapy treatment: Garden Oaks Veterinary Clinic, Bayou City Veterinary Hospital, Memorial-610 Hospital for Animals, and Sugar Land Veterinary Specialists.

In order for a dog to be considered as a candidate — though it is ultimately up to the veterinarian on whether the T-cell therapy is right for specific dogs — the dogs must weigh more than 8 pounds, not be allergic to mouse or cow products and have no active autoimmune diseases.

The company also launched a new clinical trial with A&M University in October, looking at the effects of CAVU's T-cell therapy coupled with reduced chemotherapy periods for dogs, from roughly 19 to 26 weeks of chemotherapy to 6 to 8 weeks.

While CAVU's therapy is currently only available for dogs, O'Connor said her team plans to modify the T-cell therapy to be administered in other animals.

"We have a lot of cat owners ask us [about treatment] and we are going to do that for the next round in funding," she said. "We're going to look at how to translate this for cats and eventually horses."

O'Connor said that CAVU will launch more clinical trials with A&M University's Small Animal Hospital in the future, with CAVU aiming to make T-cell therapy treatments for cats and horses available in 2020.

Looking back, O'Connor said she has come a long way in her career path: from working with sea animals at the Newport Aquarium in Kentucky to studying human immunology and toxicology, but she's returned to studying animals.

"It's amazing how I pivoted, but at the end of the day I kind of came back to animals … and I came back full circle in a way I could have never expected," she said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.

International Space Station welcomes astronauts from successful Axiom Mission 4

Out In Space

The first astronauts in more than 40 years from India, Poland and Hungary arrived at the International Space Station on Thursday, ferried there by SpaceX on a private flight.

The crew of four will spend two weeks at the orbiting lab, performing dozens of experiments. They launched Wednesday from NASA’s Kennedy Space Center.

America’s most experienced astronaut, Peggy Whitson, is the commander of the visiting crew. She works for Axiom Space, the Houston company that arranged the chartered flight.

Besides Whitson, the crew includes India’s Shubhanshu Shukla, a pilot in the Indian Air Force; Hungary’s Tibor Kapu, a mechanical engineer; and Poland’s Slawosz Uznanski-Wisniewski, a radiation expert and one of the European Space Agency’s project astronauts on temporary flight duty.

No one has ever visited the International Space Station from those countries before. The time anyone rocketed into orbit from those countries was in the late 1970s and 1980s, traveling with the Soviets.

“It’s an honor to have you join our outpost of international cooperation and exploration," NASA's Mission Control radioed from Houston minutes after the linkup high above the North Atlantic.

The new arrivals shared hugs and handshakes with the space station's seven full-time residents, celebrating with drink pouches sipped through straws. Six nations were represented: four from the U.S., three from Russia and one each from Japan, India, Poland and Hungary.

"It’s so great to be here finally. It was a long quarantine," Whitson said, referring to the crew's extra-long isolation before liftoff to stay healthy.

They went into quarantine on May 25, stuck in it as their launch kept getting delayed. The latest postponement was for space station leak monitoring, NASA wanted to make sure everything was safe following repairs to a longtime leak on the Russian side of the outpost.

It's the fourth Axiom-sponsored flight to the space station since 2022. The company is one of several that are developing their own space stations due to launch in the coming years. NASA plans to abandon the International Space Station in 2030 after more than three decades of operation, and is encouraging private ventures to replace it.

Screen-free hiking app developed in Houston earns 'Best of the Best' award

Peak Prize

An AI-powered, screen-free hiking system developed by Varshini Chouthri, a recent industrial design graduate from the University of Houston, has received Red Dot’s “Best of the Best” award, which recognizes the top innovative designs around the world.

Known as NOMAD, the system aims to help users stay in the moment while still utilizing technology. It will go on to compete for the Red Dot Luminary Award, the highest recognition given at the international event.

“NOMAD was truly a passion project, inspired by years of hiking growing up, where the outdoors became a place of peace, challenge, and reflection,” Chouthri said in a news release.

“I wanted to design something supporting those kinds of experiences by helping hikers feel more grounded and confident while staying present in nature. It was a way to give back to the moments that made me fall in love with the outdoors in the first place.”

The app “reimagines” outdoor exploration by removing the dependence on screens by using adaptive AI, contextual sensing, and an optional, wearable companion device. It employs a circular learning model that enables hikers to receive real-time guidance, safety alerts, personalized trip planning, hands-free navigation and more through a natural interface, according to UH.

NOMAD was developed at the Hines College of Architecture and Design’s PXD LAB. In 2023, Lunet, developed by David Edquilang at Hines College, received the “Best of the Best” recognition and went on to win the Red Dot Luminary Award.

The PXD LAB offers a platform to expand concepts into system-level designs that address real-world challenges, according to UH.

“Varshini’s work on NOMAD exemplifies the future-focused, systems-driven thinking we promote in the Advanced UX Design curriculum,” Min Kang, director of PXD LAB, added in the release. “NOMAD goes beyond being just a product; it reimagines how technology can enhance outdoor exploration without disrupting the experience.”

In addition to the Red Dot honors, NOMAD has already earned distinction from the FIT Sport Design Awards and was a finalist for the International Design Excellence Awards (IDEA) presented by the Industrial Designers Society of America.